Recent candidate molecular markers: Vitamin D signaling and apoptosis specific regulator of p53 (ASPP) in breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1727-1735

  Patel, Jayendra B ^a   Patel, Kinjal D ^a   Patel, Shruti R ^a   Shah, Franky D ^a   Shukla, Shilin N ^a   Patel, Prabhudas S ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Apoptotic specific protein of p53; Breast cancer; Molecular biomarkers; Vitamin D signaling pathway

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; PPP1R13B PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER; VITAMIN D;

BREAST TUMOR; FEMALE; HUMAN; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; FEMALE; HUMANS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VITAMIN D;

EID: 84872679521     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1727     Document Type: Article

References (69)

1. Bala DV, Duffy SW, Patel DD, et al (2003). Breast cancer, reported dietary intakes and dietary biomarkers: A case control study in Gujarat, India. Res Adv in Cancer, 3, 219-29.
2. Bala DV, Patel DD, Duffy SW, et al (2001). Role of dietary intake and biomarkers in risk of breast cancer: A case control study. APJCP, 2, 123-30.
3. Bergamaschi D, Samuels Y, Jin B, et al (2004). ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol, 24, 1341-50.
4. Bergamaschi D, Samuels Y, O'Neil NJ, et al (2003). iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet, 33, 162-7.
5. Bergamaschi D, Samuels Y, Sullivan A, et al (2006). iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet, 38, 1133-41.
6. Bertone-Johnson ER (2009). Vitamin D and Breast cancer. Ann Epidemiol, 19, 462-7.
7. Brodie AMH, Lu Q, Long BJ, et al (2001). Aromatase and COX- 2 expression in human breast cancers. J Steroid Biochem Mol Biol, 79, 41-7.
8. Brueggemeier RW, Quinn AL, Parrett ML, et al (1999). Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett, 140, 27-35.
9. Chen J, Xie F, Zhang L, Jiang WG (2010). iASPP is overexpressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer, 10, 694.
10. Cobleigh MA, Tabesh B, Bitterman P, et al (2005). Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res, 11, 8623-31.
11. Colston KW, Hansen CM (2002). Mechanism of implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer, 9, 45-59.
12. Deeb KK, Trump DL, Johnson CS (2007). Vitamin D signaling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer, 7, 684-700.
13. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
14. Gorina S, Pavletich NP (1996). Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science, 274, 1001-5.
15. Hedenfalk I, Duggan D, Chen Y, et al (2001). Gene-expression profiles in hereditary breast cancer. N Engl J Med, 344, 539-48.
16. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
17. Jiang F, Bao J, Li P, Nicosia SV, Bai W (2004). Induction of ovarian cancer cell apoptosis by 1, 25 dihydroxyvitamin D3 through the down regulation of telomerase. J Biol Chem, 279, 53213-21.
18. Ju H, Lee KA, Yang M, et al (2005). TP53BP2 locus is associated with gastric cancer susceptibility. Int J Cancer, 117, 957-60.
19. Koli KJ, Keski-Oja (2000). 1 alpha 25 dihdroxyvitamin D3 and its analogues downregulate cell invasion - associated proteases in cultured malignant cells. Cell growth differ, 11, 221-9.
20. Krishnan AV, Feldman D (2011). Mechanism of the anticancer and anti inflammatory action of vitamin D. Annu Rev Pharmacol Toxicol, 51, 311-36
21. Krishnan AV, Swami S, Feldman D (2010). Vitamin D and breast cancer: Inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol, 121, 343-8.
22. Lettre G, Kritikou EA, Jaeggi M et al (2004). Genome-wide RNAi identifies p53-dependent and -independent regulators of germ cell apoptosis in C. elegans. Cell Death Differ, 11, 1198-203.
23. Li G, Wang R, Gao J, et al (2011). RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells. Mol Cell Biochem, 350, 193-200.
24. Liu H, Wang M, Diao S, et al (2009). siRNA-mediated downregulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53. Leuk Res, 33, 1243-8.
25. Liu T, Li L, Yang W, et al (2011). iASPP is important for bladder cancer cell proliferation. Oncol Res, 19, 125-30.
26. Liu ZJ, Cai Y, Hou L, et al (2008). Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest, 26, 878-82.
27. Liu ZJ, Lu X, Zhang Y, et al (2005). Downregulated mRNA expression of ASPP and the hypermethylation of the 5'-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett, 579, 1587-90.
28. Maguire O, Campbell (2010). Vitamin D and p 53 - differentiating their relationship in AML. Cancer Biol Ther, 10, 351-3.
29. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer related inflammation. Nature, 454, 436-44.
30. McCullough ML, Bostick RM, Mayo1 TL (2009). Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr, 29, 111-32.
31. Mori S, Ito G, Usami N, et al (2004). p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer, 100, 1673-82.
32. Narvaez CJ, Zinser G, Welsh J (2001). Functions of 1a25- dihydroxyvitamin D3 in mammary gland: from normal development to breast cancer. Steroids, 66, 301-8.
33. Nexo BA, Vogel U, Olsen A, et al (2008). Linkage disequilibrium mapping of a breast cancer susceptibility locus near RAI/ PPP1R13L/iASPP. BMC Med Genet, 9, 56.
34. Park SW, An CH, Kim SS, Yoo NJ, Lee SH (2010). Mutational analysis of ASPP1 and ASPP2 genes, a p53-related gene, in gastric and cololorectal cancers with microsatellite instability. Gut Liver, 4, 292-3.
35. Parker JS, Mullins M, Cheang MC, et al (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol, 27, 1160-7.
36. Parkin DM, Whelan SL, Feraly J, Storm H. Cancer incidence in five continents, vol. 1-8. IARC CancerBase No.7 (Internet). Lyon: IARC, 2005. Available at http://www.dep.iarc.fr/.
37. Patel PS, Baxi BR, Adhvaryu SG, Balar DB (1990a). Evaluation of serum sialic acid, heat stable alkaline phosphatase and fucose as markers of breast carcinoma. Anticancer Res, 10, 1071-4.
38. Patel PS, Baxi BR, Adhvaryu SG, Balar DB (1990b). Individual and combined usefulness of lipid associated sialic acid, mucoid proteins and hexoses as tumor markers in breast carcinoma. Cancer Lett, 51, 203-8.
39. Patel PS, Patel MM, Raval GN, et al (1998). Seromucoid fraction: a useful biomarker for patients with breast cancer. Am J Clin Oncol, 21, 258-62.
40. Patel PS, Raval GN, Patel MM, Balar DB, Patel DD (1996). Electrophoretic pattern of serum glycoproteins on polyacrylamide disc gel in patients with breast cancer. Anticancer Res, 16, 2089-94.
41. Raval GN, Parekh LJ, Patel DD, et al (2004). Clinical usefulness of alterations in sialic acid, sialyltransferase and sialoproteins in breast cancer. Ind J Clin Biochem, 19, 60-71.
42. Raval GN, Parekh LJ, Patel MM, et al (1997). Role of sialic acid and alkaline DNase in breast cancer. Int J Biol Markers, 12, 61-7.
43. Robinson RA, Lu X, Jones EY, Siebold C (2008). Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure, 16, 259-68.
44. Rukin NJ, Strange RC (2007). What are the frequency, distribution, and functional effects of vitamin D receptor polymorphisms as related to cancer risk. Nutr Rev, 65, 96-101.
45. Samuel S, Sitrin MD (2008). Vitamin D's role in cell proliferation and differentiation. Nutr Rev, 66, 116-24.
46. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al (2001). ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell, 8, 781-94.
47. Sgroi DC, Teng S, Robinson G, et al (1999). In vivo gene expression profile analysis of human breast cancer progression. Cancer Res, 59, 5656-61.
48. Shah FD, Patel JB, Shukla SN, Shah PM, Patel PS (2009a). Evaluation of plasma non-enzymatic antioxidants in breast cancer etiology. APJCP, 10, 91-6.
49. Shah FD, Shukla SN, Shah PM, Patel HR, Patel PS (2008). Significance of alterations in plasma lipid profile levels in breast cancer. Integr Cancer Ther, 7, 33-41.
50. Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS (2009b). Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer, 46, 194-202.
51. Simpson PT, Vargas AC, Al-Ejeh F, et al (2011). Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. Hum Pathol, 42, 153-65.
52. Slattery ML (2007). Vitamin D Receptor Gene (VDR) Associations with Cancer. Nutr Rev, 65, 102-4.
53. Slee EA, Gillotin S, Bergamaschi D et al (2004). The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene, 23, 9007-16.
54. Stadler ZK, Come SE (2009). Review of gene-expression profiling and its clinical use in breast cancer. Crit Rev Oncol Hematol, 69, 1-11.
55. Su D, Ma S, Liu P, et al (2007). Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 56, 281-8.
56. Thill M, Fischer D, Hoellen F, et al (2010a). Prostaglandin metabolising enzymes and PGE2 are inversely correlated with vitamin D receptor and 25(OH)2D3 in breast cancer. Anticancer Res, 30, 1673-9.
57. Thill M, Fisher D, Kelling K, et al (2010b). Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostanglandin dehydrogenase (15- PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol, 121, 387-90.
58. Thorne J, Campbell MJ (2011). The molecular cancer biology of the VDR. Vitamin D and Cancer, 2, 25-52.
59. Tokar EJ, Webber MM (2005). Cholecalciferol (Vitamin D3) inhibits growth and invasion by up regulating nuclear receptors and 25- hydroxylase(CYP27A1) in human prostate cancer cells. Clin Exp Metastasis, 22, 275-84.
60. Trigiante G, Lu X (2006). ASPP [corrected] and cancer. Nat Rev Cancer, 6, 217-26.
61. Ventura AC, Merajver SD (2008). Genetic determinants of aggressive breast cancer. Annu Rev Med, 59, 199-212.
62. Verlinden L, Verstuyf A, Convents R, et al (1998). Action of 1, 25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol, 142, 57-65.
63. Vives V, Su J, Zhong S, et al (2006). ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev, 20, 1262-7.
64. Wagner N, Wegner KD, Schley G, et al (2003). 1, 25 dihydroxyvitamin D3 induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl2 and bax. Exp Eye Res, 77, 1-9.
65. Welsh J, Wietzke JA, Zinser GM, et al (2003). Impact of the vitamin D3 receptor on growth regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol, 83, 85-92.
66. Yang JP, Hori M, Sanda T, Okamoto T (1999). Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem, 274, 15662-70.
67. Ylikomi T, Laaksi I, Lou YR, et al (2002). Antiproliferative action of vitamin D. Vitam Horm, 64, 357-406.
68. Zhang B, Xiao HJ, Chen J, Tao X, Cai LH (2011). Inhibitory member of the apoptosis-stimulating protein of p53 (ASPP) family promotes growth and tumorigenesis in human p53- deficient prostate cancer cells. Prostate Cancer Prostatic Dis, 14, 219-24.
69. Zhao J, Wu G, Bu F, et al (2010). Epigenetic silence of ankyrinrepeat- containing, SH3-domain-containing, and prolinerich- region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology, 51, 142-53.